A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

Nomoto, H.; Miyoshi, H.; Furumoto, T.; Oba, K.; Tsutsui, H.; Miyoshi, A.; Kondo, T.; Tsuchida, K.; Atsumi, T.; Manda, N.; Kurihara, Y.; Aoki, S.; SAIS Study Group

A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

Nomoto, H.; Miyoshi, H.; Furumoto, T. et al.

2016

Permalink : https://hdl.handle.net/2115/68417

このアイテムのアクセス数:849件（2026-08-19 17:39 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
biomedfrontiers_miyoshi	pdf	217 KB	440

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/68417
タイトル	A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)
著者	Nomoto, H. ; Miyoshi, H. ; Furumoto, T. ; Oba, K. ; Tsutsui, H. ; Miyoshi, A. ; Kondo, T. ; Tsuchida, K. ; Atsumi, T. ; Manda, N. ; Kurihara, Y. ; Aoki, S. ; SAIS Study Group
著者名 Nomoto, H.
e-Rad_Researcher 30360902 著者名 Miyoshi, H.
著者名 Furumoto, T.
著者名 Oba, K.
著者名 Tsutsui, H.
著者名 Miyoshi, A.
著者名 Kondo, T.
著者名 Tsuchida, K.
著者名 Atsumi, T.
著者名 Manda, N.
著者名 Kurihara, Y.
著者名 Aoki, S.
著者名 SAIS Study Group
言語	英語
発行日	2016-04
出版者	World Biomedical Frontiers
抄録	Objective: Glucagon-like peptide-1 (GLP-1) improves hyperglycemia, and it has been reported to have favorable effects on atherosclerosis. However, it has not been fully elucidated whether GLP-1 is able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of the GLP-1 analogue, liraglutide on endothelial function and glycemic metabolism compared with insulin glargine therapy. Materials and Methods: In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8 %) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks. Flow mediated dilatation (FMD), a comprehensive panel of hemodynamic parameters (Task Force Monitor), and serum metabolic markers were assessed before and after the treatment period. Results: A greater reduction (worsening) in %FMD was observed in the glargine group, although this change was not statistically different from the liraglutide group (liraglutide; 5.7 to 5.4 %, glargine 6.7 to 5.7 %). The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group. Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early liraglutide therapy did not affect endothelial function but may provide favorable effects on beta-cell function and cardioprotection in type 2 diabetics without advanced atherosclerosis.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	2328-0166
関連情報	URI http://biomedfrontiers.org/diabetes-obesity-2016-16/
関連情報 (isPartOf)	Title World Biomedical Frontiers